Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies
{{output}}
Inhibitor antibodies to factor VIII arise in a substantial minority of patients with hemophilia A treated with replacement therapy; factor IX inhibitors in treated hemophilia B patients are considerably less common. As replacement therapy is not feasible in mo... ...
